(Q36735424)

16 August 2017

1 reference

title

Update on peritoneal dialysis solutions (English)

1 reference

16 August 2017

0 references

1 reference

C W McIntyre

1

1 reference

PubMed ID

17299524

16 August 2017

language of work or name

English

0 references

publication date

14 February 2007

1 reference

16 August 2017

1 reference

16 August 2017

71

1 reference

16 August 2017

6

1 reference

16 August 2017

486-490

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.ki.5002109

16 August 2017

0 references

cites work

Bicarbonate and bicarbonate/lactate peritoneal dialysis solutions for the treatment of infusion pain

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002109

7 January 2021

In vitro biocompatibility performance of Physioneal.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002109

7 January 2021

Glucose degradation products in peritoneal dialysis fluids: do they harm?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002109

7 January 2021

Peritoneal transport characteristics with glucose polymer based dialysate

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002109

7 January 2021

Icodextrin: a review of its use in peritoneal dialysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002109

7 January 2021

Long-term use of 1.1% amino acid dialysis solution in hypoalbuminemic continuous ambulatory peritoneal dialysis patients.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002109

7 January 2021

3,4-di-deoxyglucosone-3-ene promotes leukocyte apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002109

7 January 2021

Immunohistochemical detection of advanced glycosylation end-products in the peritoneum and its possible pathophysiological role in CAPD

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002109

7 January 2021

Peritoneal dialysis with solutions low in glucose degradation products is associated with improved biocompatibility profile towards peritoneal mesothelial cells.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002109

7 January 2021

Glucose degradation products (GDP) retard remesothelialization independently of d-glucose concentration

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002109

7 January 2021

Longitudinal membrane function in functionally anuric patients treated with APD: data from EAPOS on the effects of glucose and icodextrin prescription

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002109

7 January 2021

Biocompatibility pattern of a bicarbonate/lactate-buffered peritoneal dialysis fluid in APD: a prospective, randomized study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002109

7 January 2021

Clinical experience with two physiologic bicarbonate/lactate peritoneal dialysis solutions in automated peritoneal dialysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002109

7 January 2021

Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002109

7 January 2021

Icodextrin improves the fluid status of peritoneal dialysis patients: results of a double-blind randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002109

7 January 2021

A decline in residual glomerular filtration during the use of icodextrin may be due to underhydration

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002109

7 January 2021

Influence of convection on the diffusive transport and sieving of water and small solutes across the peritoneal membrane

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002109

7 January 2021

3,4-Dideoxyglucosone-3-ene induces apoptosis in renal tubular epithelial cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002109

7 January 2021

Glycemic control in diabetic CAPD patients assessed by continuous glucose monitoring system (CGMS).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002109

7 January 2021

Acute metabolic effects of dialysis fluids during CAPD.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002109

7 January 2021

Patients receiving maintenance dialysis have more severe functionally significant skeletal muscle wasting than patients with dialysis-independent chronic kidney disease.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002109

7 January 2021

Effects of an amino acid dialysate on leucine metabolism in continuous ambulatory peritoneal dialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002109

7 January 2021

Treatment of malnourished CAPD patients with an amino acid based dialysate.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002109

7 January 2021

Acute plasma ghrelin and leptin responses to oral feeding or intraperitoneal hypertonic glucose-based dialysate in patients with chronic renal failure

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002109

7 January 2021

Glucose-containing peritoneal dialysis fluids regulate leptin secretion from 3T3-L1 adipocytes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002109

7 January 2021

Beneficial effects of icodextrin on plasma level of adipocytokines in peritoneal dialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002109

7 January 2021

Vascular calcification and cardiovascular function in chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002109

7 January 2021

Dialysate as food: combined amino acid and glucose dialysate improves protein anabolism in renal failure patients on automated peritoneal dialysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5002109

7 January 2021

Identifiers

DOI

10.1038/SJ.KI.5002109

1 reference

16 August 2017

1 reference

PubMed ID

17299524